Alvotech is trading at ISK 608, down -4.10%, as biotechnology stocks decline alongside the sector ETF, which is down 4.24% during the regular session.
- Broader risk-off sentiment, weaker equity futures, higher global yields, and geopolitical concerns are pressuring risk-sensitive shares.
- The FDA accepted Alvotech’s AVT80 application for review on August 31, 2026; the positive company update does not explain today’s decline.